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The bariatric team at Waterfall City Hospital in Gauteng has performed 820 metabolic surgeries under the guidance of an 
extended team, and with comprehensive recordkeeping. Baseline profiling on more than 50 variables afforded insight into 
patients undergoing surgery. The available outcome data over three years were comparable with those in the documented 
literature. The attempted weight loss period prior to agreeing to surgery was 16–18 years. Weight loss in the overall cohort was 
29% at three years, with a two-year outcome as follows: diabetes mellitus remission of 81.6% in males and 83.1% in females, full 
and part-hypertension resolution of 84.8% in males and 74.6% in females, hyperlipidaemia on no treatment of 76.8% in males 
and 72.1% in females, and sleep apnoea of 75.5% in males and 76.8% in females. Separating out the diabetic group indicated a 
diabetes mellitus remission of 73.9% in males and 75.1% in females at one year. Improvement in the components of metabolic 
syndrome was demonstrated in the total cohort. There was an worse profile and higher risk in the male patients. Similarly, higher 
risk was recorded in the biliopancreatic diversion-duodenal switch cohort, and there was a higher percentage of elected diabetic 
patients. A wide range of revision surgery was performed, with a higher complication rate (20%) experienced compared to that 
recorded with the primary surgeries. The morbidity data were separated into medical and surgical morbidity. Major medical 
morbidity was documented at 5.6% and surgical morbidity at 3.9%. Surgical morbidity in the first 250 cases was reported to be 
6% vs. 2.7% in the last 570 cases. Mortality for the cohort was noted to be 0.1%.
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Introduction
Countries in transition from being undeveloped to developed, 
such as South Africa, are currently affected by the rapid rise in 
noncommunicable diseases, such as obesity.1 An increased rate of 
obesity is prevalent across all economic levels, and ethnic and age 
groups.2 Associated diseases, such as type 2 diabetes mellitus, 
hypertension and ischaemic heart disease (IHD) are high in the 
population,3–5 and pose a challenge to the government and 
private sector medicine. Combined figures obtained in 1998 for 
obesity and overweight (body mass index (BMI) > 25 kg/m2) in the 
adult population across all ethnic groups were 57% for women 
and 29% for men.6 This trend has been confirmed by more recent 
data from the early 2000s.7 Morbid obesity (BMI > 40 kg/m2) has 
not been determined in any the meaningful longitudinal studies 
in South Africa, but the prevalence of obesity (BMI > 30 kg/m2) is 
estimated to be between 20% and 34% in women and between 
3% and 20% in men, depending on the ethnic group and socio-
economic standing.8 Misrepresentation of health information 
from the 1960s until the late 1980s led to the concept of “benign 
obesity” in the black population.9 This concept has compounded 
the problem of rampant obesity and diabetes in South for many 
years in certain ethnic groups.10
Obesity prevention and treatment should be multifaceted and 
tailored to every country’s demographics, socio-political 
circumstances, pathophysiology and resources. In order to secure 
maximum benefit for economic resources, it is essential that 
research and interpretation are based on ongoing and accurate 
data collection with respect to baseline patient profiles in each 
treatment modality. In addition, outcome data need to be collected.
A programme for a Centre of Excellence for Metabolic Medicine 
and Surgery SA was launched in South Africa in 2005. The centres 
are administered by a single administrative office. The centre at 
Netcare Waterfall City Hospital performs 70% of the volume of 
metabolic surgery for Netcare Limited in South Africa. Since 
metabolic surgery appears to be markedly more efficient than 
the usual care for diabetes mellitus management in the obese,11,12 
as well as being more successful in the prevention of diabetes 
mellitus,13 it is imperative that healthcare services employ a 
definitive strategy to grow this field of medicine in the future. 
Therefore, the main aim of the paper was to document baseline 
and outcome data in South Africa for the first time, and to create 
a template for future and ongoing critical analysis pertaining to 
the arena of funders and health economics in this country.
Method
Patient variables were collected prospectively and consecutively 
using a custom-designed programme at baseline, at three months 
and then annually. Data collection took place over a period of four 
consecutive years. Data were entered and stored on the database 
in a blinded manner. Data collection was performed with the 
written consent of the patients, in accordance with the Helsinki 
Declaration of 1961, and with the permission of the Netcare 
Limited ethics committee. Chemical, clinical and radiological 
analyses form part of patients’ routine preparation, management 
and follow-up data collection. Variables at baseline included 50 
clinical, biochemical, psychological, dietary and social parameters. 
Data collection and follow-up were carried out by a single 
designated endocrinologist, metabolic surgeon, psychologist, 
psychiatrist and two dietitians. A 6–12 month window period was 
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incorporated to capture the data on remission. This was needed in 
order to accommodate a time variance in the patients’ follow-up 
schedules and the database kept for percentage statistics on the 
follow-up visits, and therefore was independent from the 
biochemical data.
The data were analysed with the XLSTAT® programme, version 
2011. Annual clinical and biochemical variables were examined 
using an unpaired Student’s t-test and the percentage presence 
of a variable, calculated on the total number (n) entered for a 
particular variable. Risk scoring and validation were based on the 
previous publication by van der Merwe and van der Walt.14
Patients were weighed in very light clothing on a Seca® scale, 
model 4413211104. The scales were calibrated in a regular and an 
identical manner. Weight was measured to one decimal place. 
Height was taken with the participants standing upright, without 
shoes, against a scale-attached ruler, and rounded to the nearest 
centimetre. The waist and hip circumferences were taken, as 
previously described by van der Merwe et al.15
Percentage body fat was measured with a GE Lunar Prodigy® 
scanner, serial number 77060GA, for patients weighing < 180 kg. 
Gallstones and hepatic steatosis were detected in a standardised 
manner by a single radiology practice, using a GE IEC® 60601–1 
sonar machine. The fasted biochemical serum samples reported 
here were collected for: glucose (3.9–6.0  mmol/l), triglycerides 
(TGs) (0.4–1.6 mmol/l), low-density lipoprotein (LDL) cholesterol 
(1.5–2.9 mmol/l), high-density lipoprotein (HDL) cholesterol (1.2–
1.9  mmol/l), alanine transaminase (ALT) (< 35.0 UI), aspartate 
transaminase (AST) (< 32.0 UI), gamma-glutamyl transferase (< 
40.0 UI), C-reactive protein (CRP) (< 5.0 mg/l) and uric acid (0.16–
0.36 mmol/l). Beckman® DxC800 pathology analysis was applied 
throughout.
Resolution of type 2 diabetes mellitus was taken to be a normal 
fasting glucose (FG) of < 3.9–6.0 mmol/l and haemoglobin A1c of 
<  4.0–6.0% (Roche® Integra 400), with the patient not requiring 
medication. Partial resolution of type 2 diabetes was reported to 
have occurred when a patient still required ongoing drug therapy 
to maintain normal biochemical values. The resolution of 
hyperlipidaemia was reported to have taken place when variables 
in the normal range for TGs 0.4–1.6 mmol/l, LDL cholesterol 1.5–
2.9  mmol/l and HDL cholesterol 1.2–1.9  mmol/l, were reported, 
while requiring no drug therapy. Partial resolution occurred if the 
patient required ongoing pharmacotherapy to achieve a normal 
result. The resolution of hypertension was taken to be a reading 
of < 130/85 mmHg (Karotkoff sounds 1 and 4), on no medication; 
and partial resolution to have taken place when ongoing 
pharmacotherapy was required in order to obtain a similar 
reading. The resolution of osteoarthritis was regarded to be 
clinically significant in the presence of a decrease or omission of 
medication, ± greater mobility by the patient.
Sleep apnoea was reported to be present with an Epworth 
Sleepiness Scale (ESS) score of more than 12, or when an overnight 
sleep polysomnography laboratory indicated an Apnoea-
Hypopnoea Index of > 5 events per hour. Depression, as well as 
eating disorders, were diagnosed by the in-house psychiatrist 
using the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition, Text Revision classification. Alcohol consumption was 
graded as per standard drink sizes in the USA containing 14 g of 
pure alcohol.16,17 Polycystic ovarian syndrome (PCOS) was 
diagnosed using the Rotterdam 2003 criteria. The New York Heart 
Association Functional Classification (NHYC) criteria were applied 
to determine functional cardiovascular status.
A government-initiated funding programme for bariatric surgery 
is not available in South Africa. Funding was driven by private 
medical funders, or alternatively by patients who self-funded. 
Private medical aid funding is governed by very strict motivational 
criteria. Patients are considered for funding at a BMI > 35 kg/m2 
with two proven criteria, including type 2 diabetes mellitus or 
hypertension treated for at least six months, nonalcoholic 
steatohepatitis (NASH) (either biochemically or on expert 
radiological sonar finding), proven sleep apnoea, 
hypercholestrolaemia (treated for at least six months), peripheral 
vascular disease, proven IHD or debilitating osteoarthritis  for 
which orthopaedic or medical management is required. These 
criteria have been accepted universally by funders based on 
calculations from actuarial teams. Alternatively, it extends to any 
patient with a BMI  >  40 kg/m2 who has repeatedly failed 
conservative intervention.
Results
The results are reported in mean  ±  standard error of the mean 
(SEM) and as percentage prevalence of the number (n) for a 
particular variable. The unpaired Student’s t-test was used for 
comparisons between groups and time periods. Unless otherwise 
indicated, n for the cohort of total surgeries was 820. The 
metabolic surgeries performed at the centre were made up of 
laparoscopic gastric bypass (LGBP) (80.6%), biliopancreatic 
diversion-duodenal switch (BPD-DS) (8.5%), laparoscopic band 
(LGB) (0.2%), revision surgery (6.3%), gastric bypass via the open 
approach (4.2%) and Lennox-Gastaut syndrome (LGS) (2.0%).
History
The past history included a history of childhood obesity (75%), a 
family history of obesity (93%), more than 10 kg weight gain since 
the age of 18 years (93%), gestational weight gain more than 10 kg 
with less than 5% post-partum weight loss (42%), the presence of 
pharmacotherapy for obesity-related co-morbidities (78%), 
pharmacotherapy with known mechanism of weight gain (42%), 
and gestational complications resulting from obesity (14%).
The mean duration in years of attempts at weight loss was 17.3 
±  0.9 years for males, and 21.4 ±  0.6 years for females. Males 
consumed 2.6 ± 0.09 meals/day and females 2.1 ± 0.09 meals/day. 
Snack consumption was 2.1  ±  0.09 in males and 2.0  ±  0.1 in 
females. 17.2% of males smoked, and 16.0% of females. Alcohol 
intake, quantified as 3–5 units per week, was associated with 
46.0% of males and 36.3% of females. Previous substance abuse 
with complete rehabilitation was diagnosed in 2.9% of the males 
and 2.5% of the females (Table 1). Patients abusing substances at 
the time of the study did not qualify for surgery.
The attempted use of previous pharmacotherapy for weight loss 
was high at 65% for males and 76% for females. A history of true 
eating disorders, bulimia and binge-eating disorders was 
relatively low, with volume and sweet eating, nibbling and stress-
related eating representing most of the abnormal eating patterns. 
The cessation of smoking was linked to weight gain in 24% of the 
males and 15% of the females (Table 2). Depression, for which 
pharmacotherapy was required, was present in 25.5% of the 
males and 53.2% of the females. Anxiety for which treatment was 
needed was also more significant in the females at 14.2%, 
compared to that in the males at 6.7%. The remainder of the 
psychoneurological profile is outlined in Table 2.
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Co-morbid diseases
Of the major co-morbidities, hyperuriceamia (47%), diabetes 
mellitus (46%), dyslipidaemia (63%), hypertension (62%), NASH 
and nonalcoholic fatty liver disease (NAFLD) (85%), sleep apnoea 
(45%), IHD (13%) and asthma and chronic obstructive pulmonary 
disease (15%) were higher in the male patient cohort (Table 3). 
The baseline and outcome data for the entire cohort of 820 
patients are shown in Table 4. A significant improvement was 
demonstrated in all of the variables by three months, with the 
exception of TGs, HDL cholesterol and uric acid, for which there 
Table 1: Gender-specific prevalence for weight loss, meal and snack intake, smoking habits, alcohol intake and substance abuse at baseline
*: Expressed as a percentage of the number in the group
Characteristics Percentage (%)*
Total (n = 820) Male (n = 207) Female (n = 613)
Years of supervised weight loss 17.3 21.4
Number of meals per day 2.6 2.1
Snack frequency per day 2.1 2.0
Cessation of smoking with > 5% weight gain 24.0 15.0
Smokers 17.2 16.0
Alcohol 46.0 36.3
Previous substance abuse 2.9 2.5
Table 2: Gender-specific prevalence in neuropsychiatric disorders at baseline
*: Expressed as a percentage of the number in the group
Characteristics Percentage (%)*




Bipolar disorder 1.0 3.8
Anxiety attacks 6.7 14.2
Psychosocial problems 8.3 12.9
Dementia 1.5 1.2
Idiopathic intracranial hypertension 1.0 0.9
Cerebrovascular accident (minor) and transient ischemic attack  2.0 2.8
Table 3: Gender-specific prevalence of major co-morbid diseases at baseline
Note: NAFLD: nonalcoholic fatty liver disease, NASH: nonalcoholic steatohepatitis
*: Expressed as a percentage of the number in the group
**: Five cases with proven cirrhosis on histology
***: Apnoea-Hypopnoea Index
Characteristics Percentage (%)*
Total (n = 820) Male (n = 207) Female (n = 613)
Hyperuricaemia and gout 47.0 19.0
Osteoarthritis 54.0 56.0




Oesophageal reflux and erosions 64.0 63.0
NAFLD and NASH** 85.0 53.0
Sleep apnoea*** 45.0 24.0
Ischaemic heart disease 13.0 6.0
Cardiomyopathy 18.0 8.0
Asthma and chronic obstructive pulmonary disease 15.0 8.0
Gallstones (previous surgery) 20.0 18.0
Renal calculi 18.0 11.0
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 19
118 Journal of Endocrinology, Metabolism and Diabetes of South Africa 2015; 20(3):115–126
It was indicated in the baseline clinical profile that the male 
patients had a statistically significant greater weight, BMI, waist 
circumference, neck circumference and blood pressure. There was 
no overall difference in the clinical risk scoring between the two 
genders. Most of the patients fell in the category of significant 
benefit from metabolic surgery. The slightly higher ESS score, 
indicating higher daytime somnolence in the males, was not 
significant, and did not clearly delineate between patients with 
established sleep apnoea on treatment, compared to those who 
were undiagnosed. On average, male patients had more associated 
co-morbid diseases (6.3 ± 0.2) than females at 5.7 ± 0.08, (Table 5).
Surgical procedures
Data were collected on 105 patients undergoing BPD-DS. The 
average BMI for the biliopancreatic diversion-duodenal switch 
(BPD-DS) cohort was 57.3  kg/m2. The clinical and biochemical 
parameters for the BPD-DS group were significantly worse than 
those for the gastric bypass group (LGBP). On average, the former 
also had 1.5 more co-morbid diseases and a higher percentage of 
diabetes mellitus at baseline (Table 6).
Diabetic versus non-diabetic patients
The differences in the baseline measurements between diabetic 
and non-diabetic patients are shown in Table 7. Data were 
available on 251 patients with type 2 diabetes mellitus. The 
patients were on oral ± insulin treatment at the time of surgery. 
Patients with type 1 diabetes were not included in the statistical 
analysis. FG levels, most of the parameters of metabolic syndrome, 
as well as uric acid, were significantly elevated in the diabetic 
mellitus cohort.
The follow-up data in the diabetic cohort over three  years for 
clinical and biochemical parameters are illustrated in Table 8. 
There was a significant improvement in all of the listed parameters.
was a significant improvement by two years. Co-morbid diseases 
were significantly reduced from a mean of 5.8 ± 0.1 to 0.41 ± 0.1 
years (p < 0.01).
Weight loss
The anthropometric variables are summarised in Table 4. Weight 
was reduced for the overall cohort from 127.0   ± 1.4 kg to 90.1   
± 3.4 kg (p < 0.01) over three years, representing a weight loss of 
29.1%. The BMI at baseline for the entire cohort was recorded as 
44.6 ± 0.4 kg/m2 and 31 ± 0.6 kg/m2 at three years at (p < 0.01). The 
baseline weight was 167.4  ± 14.0 kg and the BMI 57.9 ± 4.7 kg/m2 
for the BPD-DS patients, versus a baseline weight of 120.0 ± 4.8 kg 
and a BMI of 42.8  ±  1.6 kg/m2 for the LGBP group, reflecting 
weight loss of 29% at the time of the one year follow-up.
Gender profiling
Of the male patients, 14% were deemed to be a significant 
anaesthetic risk versus 7.9% within the female cohort. This 
difference was accounted for by the higher prevalence of severe 
sleep apnoea (37.7% vs. 24.1%) and a higher NYHC staging in the 
males (42% vs. 33%). There was no significant difference in the 
litetime history taking for preoperative pulmonary embolism 
(5.7% vs. 5.1%) or deep vein thrombosis (4.8% vs. 5.6%) for the 
males versus females. The presence of infertility (14%) and PCOS 
(19%) in the female patients was high. A further 18% reported 
undefined hormonal abnormalities. Twelve per cent of the 
patients in the female cohort were in menopause for more than 
two  years. Documented low serum testosterone levels were 
present in 15% of the males. Urinary incontinence, requiring 
surgical intervention, was the primary reason for referral for 4% of 
the patients. Three per cent of the patients had glomerulopathy, 
with significant renal dysfunction. Five patients underwent 
metabolic surgery while on haemodialysis, while awaiting renal 
transplantation.
Table 4: Baseline and follow-up data on the total surgical cohort
Note: ALT: alanine transaminase, AST: aspartate transaminase, BMI: body mass index, CRP: C-reative protein, DBP: diastolic blood pressure, FG: fasting glucose, GGT: gamma-
glutamyl transferase, HDL: high-density lipoprotein, LDL: low-density lipoprotein, SBP: systolic blood pressure, TG: triglycerides
*: Expressed as mean ± standard error of the mean
**: p < 0.05











Weight (kg) 127 ± 1.4 101 ± 1.2*** 91 ± 1.1*** 87.2 ± 2.0*** 90.1 ± 3.4***
BMI (kg/m²) 44.6 ± 0.4 36 ± 0.4*** 32 ± 1.1*** 30.7 ± 0.6*** 31 ± 0.6***
Waist circumference (cm) 123 ± 1.0 104 ± 1.0*** 95 ± 0.9*** 93 ± 1.7*** 97 ± 3.0***
Hip circumference (cm) 133 ± 0.8 118 ± 1.0*** 113 ± 1.0*** 108 ± 1.2*** 111 ± 2.2***
Neck circumference (cm) 43.5 ± 0.3 38 ± 0.5** 37 ± 0.3** 36 ± 0.5*** 37 ± 0.6***
SBP (mmHg) 147 ± 1.0 134 ± 0.8** 132 ± 1.0** 132 ± 1.5** 132 ± 2.3**
DBP (mmHg) 89 ± 2.0 80 ± 0.6** 79 ± 0.8** 80 ± 0.9 80 ± 1.7**
Co-morbidities 6 ± 0.1 0.5 ± 0.04*** 0.5 ± 0.7*** 0.5 ± 0.08*** 0.5 ± 0.1***
FG (mmol/l 6.8 ± 0.1 5.3 ± 0.1** 4.9 ± 0.05** 4.9 ± 0.1*** 5.0 ± 0.2***
TGs (mmol/l) 1.8 ± 0.05 1.4 ± 0.4 1.2 ± 0.04 1.1 ± 0.05** 1.2 ± 0.1**
HDL cholesterol (mmol/l) 1.1 ± 0.02 1.2 ± 0.04 1.7 ± 0.14 1.7 ± 0.05** 1.6 ± 0.08**
LDL cholesterol (mmol/l) 3.3 ± 0.05 2.2 ± 0.04 2.8 ± 0.14** 2.5 ± 0.08*** 2.4 ± 0.1**
ALT (U/l) 31 ± 0.9 29 ± 0.9** 25 ± 0.9** 24 ± 1.2** 22 ± 1.4**
AST (U/l) 2 5 ± 0.5 24 ± 0.5 24 ± 0.6 23 ± 0.8 21 ± 1.4
GGT (U/l) 38 ± 2.1 26 ± 1.1** 23 ± 2.0*** 19 ± 1.6*** 20 ± 2.0**
Uric acid (mmol/l) 0.49 ± 0.06 0.41 ± 0.05 0.44 ± 0.02 0.3 ± 0.02*** 0.3± 0.03***
CRP (mg/l) 12 ± 0.6 9 ± 0.2 5 ± 0.2** 5 ± 0.2** 5 ± 0.5**
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Diabetics
Full remission of diabetes of 73.9% in the males and 75.0% in the 
females was documented at one  year. At three years, full 
hypertension remission was present in 83%, full hyperlipidaemia 
remission in 82%, full remission of sleep apnoea in 85% and full 
osteoarthritis remission in 58%, of the diabetic group of patients 
(Table 10). The remission of additional co-morbidities is also 
illustrated in Table 10.
Disease remission
Gender
Compared to the male patients, a higher percentage resolution of 
hypertension and sleep apnoea at two years was demonstrated in 
the female cohort of patients. In addition, 92.0% of the females 
were not taking medication for co-morbid diseases at two years, 
compared to the 82.7% of the male patients (Table 9). No 
worsening diabetes was observed in the two genders.
Table 5: Gender-specific clinical baseline data
Note: BMI: body mass index, DBP: diastolic blood pressure, DXA: dual energy X-ray absorptiometry, SBP: systolic blood pressure
*: Expressed as mean ± standard error of the mean
**: p < 0.01, unpaired t-test for males versus females
***: p < 0.05
Characteristics Males* (n = 207) Females* (n = 613)
Total (n = 820)
Waist circumference (cm) 140 ± 1.4** 116 ± 0.8
Hip circumference (cm) 137 ± 1.8 132 ± 0.8
Neck circumference (cm) 49 ± 0.7*** 41 ± 0.3
Adjusted neck circumference (cm) 57 ± 1.4** 454 ± 0.5
Weight (kg) 153 ± 2.8** 119 ± 1.0
BMI (kg/m²) 48.3 ± 0.9*** 43.6 ± 0.3
SBP (mmHg) 157 ± 1.5*** 143 ± 0.7
DBP (mm Hg) 93 ± 1.2*** 86 ± 1.4
Average Epworth Sleepiness Scale score 12 ± 0.5 10 ± 0.3
Average co-morbid diseases 6.3 ± 0.2 5.7 ± 0.1
Clinical risk factor score 21 20
DXA body fat (%) 42 49
Table 6: Baseline data for gastric bypass procedure versus biliopancreatic diversion-duodenal switch (including laparoscopic and open surgery)
Note: ALT: alanine transaminase, AST: aspartate transaminase, BPD-DS: biliopancreatic diversion-duodenal switch, BMI: body mass index, CRP: C-reactive protein, DBP: 
diastolic blood pressure, FG: fasting glucose, GBP: gastric bypass procedure, GGT: gamma-glutamyl transferase, HDL: high-density lipoprotein, LDL: low-density lipoprotein, 
SBP: systolic blood pressure, TG: triglycerides
*: Expressed as mean ± standard error of the mean
**: p < 0.0001, unpaired t-testfor biliopancreatic diversion-duodenal switch versus gastric bypass procedure
***: p < 0.001
****: p < 0.05




Waist circumference (cm) 168 ± 13.0** 116 ± 0.8
Hip circumference (cm) 155 ± 4.5** 132 ± 0.8
Neck circumference (cm) 47 ± 3.7** 41 ± 0.3
Adjusted neck circumference (cm) 57 ± 1.4*** 45 ± 0.5
Weight (kg) 168 ± 13.0** 119 ± 1.0
BMI (kg/m2) 57.9 ± 4.5** 43.6 ± 0.3
SBP (mmHg) 151 ± 11.2**** 143 ± 0.7
DBP (mmHg) 84 ± 6.0 86 ± 1.4
Co-morbidities 6.9 ± 0.2** 5.7 ± 0.1
FG (mmol/l) 6.6 ± 0.5**** 6.0 ± 0.3
TGs (mmol/l) 1.6 ± 0.1**** 1.7 ± 0.1
HDL cholesterol (mmol/l) 1.1 ± 0.1*** 1.3 ± 0.1
LDL cholesterol (mmol/l) 3.1 ± 0.2**** 3.3 ± 0.1
ALT (UI) 34 ± 2.7 31 ± 1.1
AST (UI) 27 ± 2.1 24 ± 0.9
GGT (UI) 38 ± 3.0 37 ± 1.4
CRP (mg/l) 18 ± 1.4*** 10 ± 0.4
Uric acid (mmol/l) 0.5 ± 0.02 0.46 ± 0.02
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 21
120 Journal of Endocrinology, Metabolism and Diabetes of South Africa 2015; 20(3):115–126
stage 3. Four (0.5%) cases with primary hyperparathyroidism with 
adenomas were identified preoperatively, and underwent 
elective parathyroidectomies for the symptomatic relief of 
hypercalcemia prior to metabolic surgery.
Pre- and postoperative endoscopy and radiology
Preoperative endoscopy revealed Helicobacter pylori in 28.5% of 
patients who underwent the procedure. All H. pylori infections 
were treated with standard triple therapy, including two broad-
spectrum antibiotics for seven  days, as well as a proton-pump 
inhibitor (PPI) for 30 days.
Nutrition, alcohol and cancer postoperatively
Food tolerance was good at three years, with only 26.1% of the 
patients dumping and 67.9% demonstrating a high level of 
compliance with their dietary instructions (Table 11). Significant 
alcohol intake post surgery and within the three-year follow-up 
was present in 4.6% of patients. Six patients (0.7%) were 
diagnosed with new-onset cancer in the follow-up period of 
three years. These included a low-grade sarcoma, non-Hodgkin’s 
lymphoma stage 3, two intermediate- and high-grade invasive 
ducal breast cancers, melanoma stage 2 and prostate cancer 
Table 7: Clinical and biochemical data on diabetic versus non-diabetic patients
Note: ALT: alanine transaminase, AST: aspartate transaminase, BMI: body mass index, CRP: C-reactive protein, DBP: diastolic blood pressure, DXA: dual energy X-ray 
absorptiometry, FG: fasting glucose, GGT: gamma-glutamyl transferase, HDL: high-density lipoprotein, LDL: low-density lipoprotein, SBP: systolic blood pressure, TGs: 
triglycerides
*: Expressed as mean ± standard error of the mean, except for percentage body fat
**: p < 0.05
***: p < 0.01, unpaired t-test for diabetic versus non-diabetic patients




BMI (kg/m²) 44.6 ± 0.4 44.5 ± 0.4
Waist circumference (cm) 123 ± 0.9 121 ± 0.8
SBP (mmHg) 147 ± 0.8 145 ± 0.7
DBP (mmHg) 88 ± 1.9 85 ± 0.5
Co-morbid diseases 5.80 ± 0.1** 4.5 ± 0.1
FG (mmol/l) 7.8 ± 0.24** 5.1 ± 0.08
Fasting TGs (mmol/l) 2.2 ± 0.06** 1.6 ± 0.08
HDL cholesterol (mmol/l) 1.0 ± 0.03** 1.4 ± 0.02
LDL cholesterol (mmol/l) 3.9 ± 0.08** 3.2 ± 0.06
ALT (UI) 43 ± 0.9*** 30 ± 0.5
AST (UI) 34 ± 1.0** 23 ± 1.4
GGT (UI) 42 ± 2.0** 32 ± 3.7
CRP (mg/l) 11 ± 0.8 11 ± 0.5
Uric acid (mmol/l) 0.56 ± 0.2*** 0.43 ± 0.3
DXA body fat (%) 49 44
Table 8: Diabetic outcome data over three years
Note: ALT: alanine transaminase, AST: aspartate transaminase, BMI: body mass index, DBP: diastolic blood pressure, FG: fasting glucose, GGT: gamma-glutamyl transferase, 
HDL: high-density lipoprotein, LDL: low-density lipoprotein, SBP: systolic blood pressure, TGs: triglycerides
*: Expressed as mean ± standard error of the mean
**: p < 0.01, unpaired t-test
***: p < 0.05
Diabetic outcome data Baseline* (n = 251)
3 years* 
(n = 107)
BMI (kg/m2) 44.6 ± 0.4 32.6 ± 1.1**
Waist circumference (cm) 123 ± 0.9 94 ± 1.7**
SBP (mmHg) 147 ± 0.8 131 ± 1.4***
DBP (mmHg) 88 ± 1.8 82 ± 1.8***
Co-morbidities 5.80 ± 0.1 0.4 ± 0.1***
FG (mmol/l) 7.8 ± 0.2 5.0 ± 0.2**
Fasting TGs (mmol/l) 2.2 ± 0.1 1.3 ± 0.1**
HDL cholesterol (mmol/l) 1.0 ± 0.1 1.69 ± 0.1***
LDL cholesterol (mmol/l) 3.9 ± 0.1 2.04 ± 0.1***
ALT (UI) 36 ± 0.8 23 ± 1.5**
AST (UI) 29 ± 0.5 22 ± 0.8***
GGT (UI) 38 ± 2.0 21 ± 2.8**
Uric acid (mg/l) 0.56 ± 0.1 0.29 ± 0.1**
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Morbidity and mortality
There was 5.6% postoperative major medical morbidity, requiring 
re-admission within 60 days or prolonged admission post surgery 
(Table 12). Minor medical morbidity at 60  days for which 
admission was not required was low at 2.6%, and included 
gastroparesis (two cases), minor pneumonia (four cases) and gout 
requiring multi-drug treatment (15 cases). Postoperative 
pulmonary embolism within six weeks from the time of surgery 
was documented in one patient only, and in another five patients 
at more than one year post surgery.
Postoperative endoscopy at three months revealed that stomal 
ulceration was present in 4.3% of patients who tested positive for 
H. pylori preoperatively, and in 16% of patients who tested negative 
for this organism preoperatively. Significant ethnic differences 
were observed with respect to the prevalence of H. pylori. 23.8% of 
patients in the Caucasian patient population tested positive, 21.0% 
of the coloured patient population, 29.6% of the Indian patient 
population and 76.1% of the black patient population. Gallstones 
were diagnosed in 20.4% of patients on preoperative sonar, with 
cholecystectomy performed at the time of surgery. Five per cent of 
patients required a cholecystectomy postoperatively.
Table 9: Gender-related difference in the resolution of disease at two years
*: Expressed as a percentage of resolution for the number in the group
**: p < 0.01 
Note: Diabetes mellitus worsened with ongoing pharmacology, diabetes mellitus treated to target




Diabetes mellitus (fully) 81.6 83.1
Diabetes mellitus (partly) 18.4 16.9
Hypertension (fully) 56.5 66.5**
Hypertension (partly) 28.3 8.1
Dyslipidaemia (no treatment) 76.8 98.9
Sleep apnoea 75.5 94.9**
Osteoarthritis (no treatment) 40.0 83.0
Osteoarthritis (incomplete) 28.9 24.7
No pharmacology 82.9 92.9
Table 10: Resolution of disease at one year in male and female diabetic patients
*: Expressed as a percentage of the number in the group
Disease resolution 1 year* (%) 3 years* (%)
Diabetes mellitus (fully) 65.0 87.5
Diabetes mellitus (partly) 35.0 12.5
Hypertension (fully) 70.5 83.0
Hypertension (partly) 20.5 12.0
Hyperlipidaemia (fully) 80.0 82.0
Hyperlipidaemia (partly) 8.6 1.0
Sleep apnoea 63.6 85.0
Osteoarthritis (fully) 48.5 58.0
Osteoarthritis (partly) 34.2 25.0
Table 11: Food tolerance and nutritional compliance over three years in the total surgical cohort
*: Expressed as a percentage of the number in the group
Food tolerance and nutritional compliance 1 year* (%), (n = 820) 3 years* (%), (n = 288)
Dumping 23.3 26.1
Meat tolerance 83.5 92.8
Bread tolerance 79.9 87.8
Lactose intolerance 16.3 22.8
Vomiting 0.5 2.5
Diarrhoea 2.4 1.2
Dietary compliance 82.4 67.9
Visits to the dietitian 96.2 83.1
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simultaneous RYGB, or revision of the RYGB to a biliopancreatic 
diversion. The remainder of cases included revision of the gastric 
pouch, revision of previous old gastric stapling of the stomach, 
and revision of vertical banded gastroplasty to RYGB or BPD-DS. 
In addition, two revisions were performed to lengthen the 
common limb in the primary surgery as a result of severe protein 
malnutrition; one for a case with BPS-DS and one for a case with 
long-limb LGBP.
Health economics and follow-up
Theatre time and length of stay improved significantly between 
2007 and 2009, and 2009 and 2012 (Figure 2). Hospital costs 
increased by 23.4% over five  years, from a mean of  ±  R45 800 
to  ±  R59 700. This cost escalation was inclusive of inflation, an 
average increase in BMI of seven index points, and a more than 
300% increase in the rate of BPD-DS operations. Follow-up of the 
patient cohort postoperatively was 96.7% at three months, 90.5% 
at one year, 82.1% at two years and 74.8% at three years.
Discussion
An improved understanding of the physiology of energy 
homeostasis and the endocrine control of food intake will form 
the basis of the evolution of effective therapeutic and preventative 
strategies in the human population. In this regard, metabolic 
surgery is ideally positioned to assist with potential mechanisms 
for novel therapies.18 However, a clear understanding of the 
impact that metabolic surgery has on health problems and the 
long-term outcome with respect to obesity is still scarce. This is 
One medical death was reported within 30 days, and one within 
90 days. The latter was a patient who advanced to a more severe 
stage of liver dysfunction and cirrhosis (LGBP), and the other died 
of suspected fatal central sleep apnoea at home on the fourth day 
postoperatively (LGBP). (The latter patient’s family refused a post-
mortem examination).
Major surgical morbidity was defined as a patient requiring 
admission for more than seven days, admission to the intensive 
care unit, or requiring re-look surgery. There was major surgical 
morbidity at 30 days of 3.9%.There was 6% major morbidity for 
the first 250 cases, and 2.7% for the next 570 cases (Figure 1). Late 
(> 30 day) major surgical morbidity was reported to be 3.4% in 
the overall cohort. Only four cases were documented in the BPD-
DS group. There was no surgical mortality. Therefore, overall 30-
day mortality was recorded as 0.1%, and included one medical 
death.
Revision surgery
Revision surgery was performed in 5.4% of patients. Of these, 
1.3% was performed on patients who had undergone the primary 
surgery at our own centre. Open revision accounted for 77% of 
the surgeries. Complications were experienced in 43% of the 
patients. Twenty per cent were regarded as major complications, 
for which more than seven days of admission was required. More 
than 80% of the surgeries were for the reversal of jejenoileal 
bypass (JIB) procedures with simultaneous RYGB, removal of 
complicated or unsuccessful laparoscopic gastric bands with 
Table 12: Major medical morbidities (5.4%) relating to primary surgery for which re-admission at 60 days, or prolonged primary admission of more 
than seven days, is required
Major medical morbidity n
Aspiration pneumonia 1
Pneumonia 8
Congestive cardiac failure 2
Central sleep apnoea 2
Protein malnutrition requiring total parental nutrition 7
Severe nausea syndrome 8
Severe gout 7
Kidney stones 9




















Figure 1: Major surgical morbidity at 30 days, expressed as a percentage 
of the number in the group
BPD/DS: biliopancreatic diversion-duodenal switch, GBP: gastric bypass procedure.


















2 h 50 min
2 h 10 min
5.1 days                                3.4 days
Figure 2: Reduction in theatre time and length of stay
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considered in the morbidly obese male population. According to 
this theory, it is speculated that the immune redistribution 
hypothesis is supported by the negative association between 
testosterone levels and insulin resistance.48,49 Fifteen per cent of 
patients in our male cohort had known levels of low testosterone. 
This figure is expected to rise as we look for it with greater 
vigilance.
The BPD-DS procedure is reserved for patients with a higher BMI, 
and a worsened co-morbid disease profile. However, it can be 
stated that BMI should not be the only selection criteria.50 A 
potentially higher degree of diabetes resolution in carefully 
selected patients is required.11,12,51 Similarly, conclusions should 
not be drawn on small cohorts of patients with a short- to 
medium-term follow-up of two  years and less.52 The three-year 
outcome data on the 251 diabetic patients in the diabetic cohort 
were as expected owing to reports in the literature of complete 
remission of diabetes in 88.5% of patients,53,54 and of comparable 
biochemical improvements in all the components of metabolic 
syndrome.55 The patients in the overall cohort sustained an 
approximated 27% overall weight loss, closely resembling that in 
a previous meta-analysis.56 Ten-year outcome data may not be 
this sustainable.57 There was a higher percentage of complete 
resolution of hypertension and sleep apnoea at two years in the 
female patients, almost certainly as a result of the less severe 
baseline profile in the females. However, a differing pathology 
between the two genders cannot be excluded.58 The metabolic 
syndrome itself might potentiate the effect of obstructive sleep 
apnoea on cardiovascular disease, with the most profound risk 
expressed in the morbidly obese category.59,60
Nonalcoholic fatty liver disease (NAFLD) includes a broad 
spectrum of liver tissue alterations, ranging from pure steatosis to 
cirrhosis, through to NASH. Obesity, especially central obesity, is 
the metabolic condition most closely associated with steatosis 
and NASH.61 The presence of NASH in the general population has 
been reported to be from 16–30% in prevalence studies, with an 
exponential increase at a BMI above 27 kg/m2.62 There was a high 
prevalence of NASH, either on sonography or biochemistry, in 
both male and female patients in our patient cohort, but 
significantly more so in the male patients (75% vs. 53%). It is likely 
that bariatric surgery plays a role in preventing and treating 
advanced liver disease, but well-designed prospective trials are 
needed to confirm this.63
Estimates of obesity prevalence in female with PCOS vary from 
35–60% in the literature,64 and it is estimated that approximately 
20% of females in the world carry this diagnosis.65 There was a 
high prevalence of both infertility and PCOS of 14% and 19%, 
respectively, in our female patient cohort. It is also recognised 
that GBP surgery affords improvement in many clinical problems 
relating to PCOS.66,67
The rate of pulmonary embolism in our immediate (six  weeks) 
postoperative patient cohort was low, and most likely to be the 
result of careful patient selection and screening, early mobilisation 
and the stringent application of our recommendation guidelines 
on the prevention of pulmonary embolism.68 Significant 
postoperative alcohol consumption was reported in 4.6% of our 
patient population. The physiological changes after surgery could 
change vulnerability to problematic alcohol use, increasing the 
lifetime risk of alcohol use disorders, and greater sensitivity to the 
intoxicating effects of alcohol.69 Adequate alcohol consumption 
screening, and preoperative preparation could assist in mitigating 
this risk.16
mainly because of the lack of prospective, systematic collection of 
data on the baseline disease profile, and follow-up of patients 
undergoing this surgery. With the exception of a few long-term 
studies,19–21 most studies report on medium-term outcome data, 
surgical complications and long-term mortality.22–24
Contrary to general misperception, obesity is not a disease of the 
last two decades only.25 Populations with a broad range of 
adiposity have existed for centuries, with those in the top quartile 
always suffering the most adverse health consequences. However, 
there are still lean individuals in all populations. Thus, although 
the heritability of obesity is high, explaining the genetically 
determined inter-individual differences in susceptibility to an 
environment that is obesity prone, does not exclude the 
possibility that individuals who exert voluntary effort can achieve 
weight loss.26,27 The measure of success that can be achieved in 
this manner is variable, and based on many biological drivers. This 
understanding is often lacking in the medical profession, public 
and media, and fosters an understanding that the “obese should 
be punished”, and not the disease of obesity.28 This, together with 
the lack of documented outcome and follow-up of bariatric 
surgery patients over the previous decade, has resulted in only 
1% of eligible patients in the morbidly obese population being 
referred for and treated with metabolic surgery in the last 
five years, despite the 13-fold increase in surgeries in the USA and 
worldwide since 1992.29,30
Although formal health economic studies on bariatric surgery 
have not been performed at our own centre, every indication is 
there that the surgery is performed in a highly cost-effective 
manner. The total cost of LGBP is estimated to be $12 500, 
compared to $26 000 in the USA.31,32 Theatre time reduced from 2 
hours 50 minutes to 2 hours 10 minutes, over a three-year period, 
and includes a 10% take on BPD-DS of the total surgeries. In 
addition, a reduction in the documented mean of 5.8 for co-
morbid diseases to 0.4, certainly places the return on capital 
investment on a par with that in the published literature.33–35 The 
outcome with respect to a reduction in the drug classes pre- and 
post surgery will be available in the near future.
Our data support the observation that bariatric surgery is 
contemplated over 1–2 decades by patients, and that most 
patients present with a history of childhood obesity and a strong 
family history of obesity.36 Therefore, our data also refute the 
notion that patients view this mode of treatment as an instant 
solution to their obesity problem. A very high percentage of 
patients attempt pharmacotherapy unsuccessfully.37 In addition, 
and contrary to popular belief, we present enough evidence that 
these patients do not all fall into the category of severe eating 
disorders. On average, they overeat by 200–400 calories daily.38
It was found in recent studies on depression, bipolar disease and 
anxiety that the lifetime history of at least one axis I diagnosis is 
high, and that a current diagnoses of axis I disorder varies from 
38–56%, and 29% for an axis II diagnosis.39–41 Our data support 
this notion.
Major co-morbidities were documented with a higher prevalence 
in male, compared to female, patients. This could, in part, be 
explained by the higher BMI index in the male patients, but in 
view of the of the higher abdominal circumference, the role of 
central obesity,42,43 as well as the role of the negative association 
between testosterone levels and insulin resistance in males, 
needs to be considered.44–47 The evolutionary origins of insulin 
resistance, as discussed by Watvi and Yajnik, also need to be 
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Concise consensus statements on metabolic surgery for health 
professionals and medical funders need to be updated.90 A wealth 
of publications has emanated in the field of obesity surgery 
worldwide, and yet misperceptions about the pathophysiology, 
perioperative mortality and morbidity, outcome data and health 
and economic benefits still persist in the medical profession, 
media and public. In addition, understandably scepticism among 
diabetologists, endocrinologists and physicians still needs to be 
addressed as they have developed fine research and treatment 
tools for the management of diabetes and other obesity-related 
co-morbidities.91–94
Despite certain practical and logistical limitations in the current 
study, we believe that it is imperative to start publishing our own 
“home-grown” data with a view to enriching our local knowledge 
base, stimulating ongoing essential research, and satisfying the 
overwhelming desire to continually improve what we know and 
practise within the Centre of Excellence  for Metabolic Medicine 
and Surgery SA.
The role of the surgical community in the disease of obesity was 
eloquently outlined by Ronald Martin:95 “The best tool, (in order) 
to an effective part of the solution to any problem, is always good 
knowledge of the fundamentals”. So once again, we have to do 
what is required, and to perfect the role that we have to play, in 
order to understand obesity.
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